Emergent BioSolutions Secures 3-Year Canadian Standing Offer for NARCAN Nasal Spray
Event summary
- Emergent BioSolutions awarded a standing offer by the Government of Canada to supply NARCAN® Nasal Spray from October 1, 2026, through September 30, 2029, with an option to extend for two additional years.
- The standing offer allows federal, provincial, and territorial organizations in Canada to procure NARCAN® Nasal Spray through individual call-ups.
- NARCAN® Nasal Spray is the only 4 mg, intranasal naloxone spray in Canada with a shelf life of four years.
- This award follows an existing 5-year standing offer between Emergent and the Government of Canada set to expire in September 2026.
The big picture
This standing offer underscores the critical role of naloxone in combating the opioid crisis, with the Canadian government's procurement strategy aimed at ensuring broad availability of overdose reversal medication. Emergent BioSolutions' continued partnership with the Government of Canada highlights the strategic importance of public-private collaborations in addressing public health challenges. The deal's scale and duration suggest a long-term commitment to opioid overdose prevention, positioning Emergent as a key player in this space.
What we're watching
- Market Expansion
- How Emergent BioSolutions will leverage this standing offer to expand its market presence in Canada and potentially other regions.
- Regulatory Dynamics
- Whether the Government of Canada's continued support for NARCAN® Nasal Spray will influence other governments to adopt similar procurement strategies.
- Execution Risk
- The pace at which Emergent can meet the demand for NARCAN® Nasal Spray under the new standing offer, given the scale of the opioid crisis in Canada.